This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: March 28, 2008
Last updated: November 1, 2016
Last verified: November 2016
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors. After a pre-randomisation period during which positron emission tomography computed tomography (PET/CT) and MRI will be conducted, patients will be randomized to receive either RO4607381 600mg po daily, or placebo po daily. PET/CT and MRI scans will be taken at intervals during the study. The anticipated time on study treatment is 2 years, and the target sample size is 100 individuals.

Condition Intervention Phase
Coronary Heart Disease Drug: Dalcetrapib (RO4607381) Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Change from baseline of MRI plaque size/burden [ Time Frame: 12 months ]
  • Change from baseline in target (plaque) to background (blood) ratio from an index vessel. [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Change from baseline in vessel magnetic resonance (MR) determined compliance [ Time Frame: 6 months ]
  • Change from baseline in vessel MR determined plaque anatomy [ Time Frame: Up to 24 months ]
  • Blood lipids,lipoproteins [ Time Frame: Throughout study ]
  • Biomarkers [ Time Frame: Up to 24 months ]
  • CHD, major coronary events, adverse events (AEs), lab parameters, blood pressure [ Time Frame: Throughout study ]

Enrollment: 130
Study Start Date: March 2008
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dalcetrapib (RO4607381) Drug: Dalcetrapib (RO4607381)
600mg po daily for 24 months
Placebo Comparator: Placebo Drug: Placebo
po daily for 24 months


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, 18-75 years of age;
  • CHD, including patients with other CHD risk factors;
  • treated appropriately for dyslipidemia;
  • clinically stable.

Exclusion Criteria:

  • previous exposure to any cholesteryl ester transfer protein (CETP) inhibitor or vaccine;
  • recent (within 3 months) clinically significant coronary events, transient ischemic attacks or cerebrovascular accident;
  • severe anemia;
  • uncontrolled hypertension;
  • poorly controlled diabetes.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00655473

United States, Florida
Jacksonville, Florida, United States, 32216
United States, Michigan
Royal Oak, Michigan, United States, 48073
United States, Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Kansas City, Missouri, United States, 64111
United States, New York
New York, New York, United States, 10029
United States, North Carolina
Statesville, North Carolina, United States, 28677
United States, Ohio
Cincinnati, Ohio, United States, 45219
Cincinnati, Ohio, United States, 45227
Cleveland, Ohio, United States, 44195
United States, Texas
Houston, Texas, United States, 77030
United States, Washington
Seattle, Washington, United States, 98108
Canada, Quebec
Montreal, Quebec, Canada, H1T 1C8
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche Identifier: NCT00655473     History of Changes
Other Study ID Numbers: NC21153
Study First Received: March 28, 2008
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Plaque, Atherosclerotic
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Pathological Conditions, Anatomical
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on September 21, 2017